Ilya Nechaev: Is it a new milestone for SCLC patients?
Ilya Nechaev, Head of Medical Affairs at BostonGene, posted on LinkedIn:
“Is it a new milestone for SCLC patients?
What a fantastic breakthrough! Today, we celebrate a significant advancement in SCLC therapy! The new IMforte study (NCT05091567) brings one more hope and demonstrates how far we’ve come in tackling this aggressive disease.
When we just started the trial with lurbinectedin, I’ll admit I was a bit skeptical – the data on efficacy was quite limited. But today, I’m thrilled to be proven wrong! It’s incredible to see how science continues to push boundaries.
Congratulations to the entire development and clinical research teams who made this outcome possible. Jazz Pharmaceuticals and Roche
Colleagues, does anyone know where these findings will be presented? ESMO-IO, ELCC, or somewhere else? Can’t wait to learn more about the magnitude of this success!”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023